Long-term remission with certolizumab pegol in Crohn's disease: Efficacy over 4.5 years in patients with no prior TNF inhibitor exposure (PRECiSE 3 study).

被引：0
|
作者：
Lichtenstein, G. [1 ]
Thomsen, O. [2 ]
Schreiber, S. [3 ]
Lawrance, I [4 ]
Hanauer, S. [5 ]
Bloomfield, R. [6 ]
Sandborn, W. [7 ]
机构：
[1] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[2] Univ Copenhagen, Copenhagen, Denmark
[3] Univ Kiel, Kiel, Germany
[4] Univ Western Australia, Fremantle Hosp, Fremantle, WA, Australia
[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[6] UCB Pharma, Slough, Berks, England
[7] Mayo Clin, Rochester, MN USA
来源：
INFLAMMATORY BOWEL DISEASES | 2011年 / 17卷
关键词：
D O I：
10.1093/ibd/17.supplement1.S51b
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S51 / S52
页数：2
相关论文
共 50 条
  • [1] Long-term Remission with Certolizumab Pegol in Crohn's Disease: Efficacy Over 4.5 Years in Patients with No Prior TNF Inhibitor Exposure (PRECiSE 3 Study)
    Lichtenstein, Gary
    Thomsen, Ole
    Schreiber, Stefan
    Lawrance, Ian
    Hanauer, Stephen
    Bloomfield, Ralph
    Sandborn, William
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S417 - S418
  • [2] Long-Term Remission With Certolizumab Pegol in Crohn's Disease: Efficacy Over 4 Years in Patients With NO Prior TNF-α Inhibitor Exposure (PRECiSE 3 Study)
    Lichtenstein, Gary
    Thomsen, Ole O.
    Schreiber, Stefan
    Lawrance, Ian C.
    Hanauer, Stephen B.
    Bloomfield, Ralph
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S165 - S165
  • [3] Long-Term Remission With Certolizumab Pegol in Crohn's Disease: Efficacy Over 5 Years in Patients With No Prior Anti-TNF Agent Exposure (PRECiSE 3 Study)
    Sandborn, William J.
    Schwartz, David A.
    Schreiber, Stefan
    Lawrance, Ian C.
    Sen, David I.
    Lichtenstein, Gary R.
    [J]. GASTROENTEROLOGY, 2011, 140 (05) : S262 - S262
  • [4] Long-term remission with certolizumab pegol in Crohn's disease: Efficacy over 5 years in patients with no prior anti-TNF agent exposure (precise 3 study)
    Sandborn, William J.
    Schwartz, David
    Schreiber, Stefan
    Lawrance, Ian C.
    Sen, David
    Lichtenstein, Gary R.
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S23 - S23
  • [5] Patients With Crohn's Disease Treated With Certolizumab Pegol Experienced Long-Term Remission Regardless of Prior TNF-α Inhibitor Exposure (PRECiSE 4 Study)
    Sandborn, William J.
    Schreiber, Stefan
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Bloomfield, Ralph
    Lichtenstein, Gary
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S9 - S9
  • [6] Long-term remission with certolizumab pegol in Crohn's disease over 3.5 years: results from the PRECiSE 3 study
    Lichtenstein, G.
    Thomsen, O.
    Schreiber, S.
    Lawrance, I
    Hanauer, S.
    Bloomfield, R.
    Sandborn, W.
    [J]. INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S12 - S13
  • [7] Long-term Remission with Certolizumab Pegol in Crohn's Disease over 3.5 Years: Results from the PRECiSE 3 Study
    Lichtenstein, Gary
    Thomsen, Ole
    Schreiber, Stefan
    Lawrance, Ian
    Hanauer, Stephen
    Bloomfield, Ralph
    Sandborn, William
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S450 - S450
  • [8] Predictors of Maintenance of Long-term Remission in Crohn's Disease Patients Treated With Certolizumab Pegol: Multivariate and Univariate Analyses From the PRECiSE 3 Study
    Sandborn, William
    Schreiber, Stefan
    Siegel, Corey
    Melmed, Gil
    McGovern, Dermot
    Pierre-Louis, Bosny
    Kosutic, Gordana
    Spearman, Marshall
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S514 - S514
  • [9] Editorial: long-term safety and efficacy of certolizumab pegol for Crohn's disease
    Cesarini, M.
    Danese, S.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (10) : 1243 - 1243
  • [10] Long-term treatment with certolizumab pegol for up to 18 months in patients with active Crohn's disease: Precise 3 efficacy results
    Schreiber, Stefan
    Hanauer, Stephen B.
    Feagan, Brian G.
    Bloomfield, Ralph
    Rutgeerts, Paul
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A504 - A504
12345